AR066175A1 - Ligandos del receptor de melanocortina de peptidos ciclicos - Google Patents
Ligandos del receptor de melanocortina de peptidos ciclicosInfo
- Publication number
- AR066175A1 AR066175A1 ARP080102546A ARP080102546A AR066175A1 AR 066175 A1 AR066175 A1 AR 066175A1 AR P080102546 A ARP080102546 A AR P080102546A AR P080102546 A ARP080102546 A AR P080102546A AR 066175 A1 AR066175 A1 AR 066175A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- arylc1
- acyl
- alkyl
- alkenyl
- Prior art date
Links
- 102000001189 Cyclic Peptides Human genes 0.000 title 1
- 108010069514 Cyclic Peptides Proteins 0.000 title 1
- 125000002252 acyl group Chemical group 0.000 abstract 12
- 125000000304 alkynyl group Chemical group 0.000 abstract 8
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 8
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 abstract 5
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 abstract 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 4
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 abstract 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000008574 D-amino acids Chemical class 0.000 abstract 3
- -1 aromatic amino acid Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan, uso de dichos compuestos para el tratamiento de mamíferos y composiciones farmacéuticas que comprenden dichos compuestos. Reivindicacion 1: Un compuesto de acuerdo con la formula (1): (R2R3)-A0-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, donde: A0 es un aminoácido aromático; A1 es Acc, HN-(CH2)m-C(O), L- o D-aminoácido; A2 es Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp o Glu; A3 es Gly, Ala, beta-Ala, Gaba, Aib, D-aminoácido; A4 es His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi o (X1,X2,X3,X4,X5)Phe; A5 es D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-BaI, D-(X1,X2,X3,X4,X5)Phe, L-Phe o D-( Et)Tyr; A6 es Arg, hArg, Dab, Dap, Lys, Orn o HN-CH((CH2)n-N(R4R5))-C(O); A7 es Trp, 1-Nal, 2-Nal, Bal, Bip, D-Trp, D-1-Nal, D-2-Nal, D-Bal o D-Bip; A8 es Gly, D-Ala, Acc, Ala, beta-Ala, Gaba, Apn, Ahx, Aha, HN-(CH2)s-C(O) o está delecionado; A9 es Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap, Orn o Lys; A10 es Acc, HN-(CH2)t-C(O), L- o D-aminoácido, o está eliminado; R1 es -OH o -NH2; R2 y R3 son, independientemente para cada ocurrencia, H, alquilo C1-30, heteroalquilo C1-30, acilo C1-30, alquenilo C2-30, alquinilo C2-30, arilC1-30alquilo, arilC1-30acilo, alquilo C1-30 sustituido, heteroalquilo C1-30 sustituido, acilo C1-30 sustituido, alquenilo C2-30 sustituido, alquinilo C2-30 sustituido, arilC1-30alquilo sustituido o arilC1-30acilo sustituido; R4 y R5 son, independientemente para cada ocurrencia, H, alquilo C1-40, heteroalquilo C1-40, acilo C1-40, alquenilo C2-40, alquinilo C2-40, arilC1-40alquilo, arilC1-40acilo, alquilo C1-40 sustituido, heteroalquilo C1-40 sustituido, acilo C1-40 sustituido, alquenilo C2-40 sustituido, alquinilo C2-40 sustituido, arilC1-40alquilo sustituido o arilC1-40acilo sustituido, alquilsulfonilo C1-40 o -C(NH)-NH2; m es, independientemente para cada ocurrencia, 1, 2, 3, 4, 5, 6 o 7; n es, independientemente para cada ocurrencia, 1, 2, 3, 4 o 5; s es, independientemente para cada ocurrencia, 1, 2, 3, 4, 5, 6 o 7; t es, independientemente para cada ocurrencia, 1, 2, 3, 4, 5, 6 o 7; y X1, X2, X3, X4, y X5 son cada uno, independientemente para cada ocurrencia, H, F, CI, Br, I, alquilo C1-10, alquilo C1-10 sustituido, alquenilo C2-10, alquenilo C2-10 sustituido, alquinilo C2-10, alquinilo C2-10 sustituido, arilo, arilo sustituido, OH, NH2, NO2, o CN; siempre que (1). R4 sea acilo C1-40, arilC1-40acilo, acilo C1-40 sustituido, arilC1-40acilo sustituido, alquilsulfonilo C1-40 o -C(NH)-NH2; y R5 es H, alquilo C1-40, heteroalquilo C1-40, alquenilo C2-40, alquinilo C2-40, arilC1-40alquilo, alquilo C1-40 sustituido, heteroalquilo C1-40 sustituido, alquenilo C2-40 sustituido, alquinilo C2-40 sustituido o arilC1-40alquilo sustituido; (2). R2 sea acilo C1-30, arilC1-30acilo, acilo C1-30 sustituido o arilC1-30acilo sustituido; y R3 sea H, alquilo C1-30, heteroalquilo C1-30, alquenilo C2-30, alquinilo C2-30, arilC1-30alquilo, alquilo C1-30 sustituido, heteroalquilo C1-30 sustituido, alquenilo C2-30 sustituido, alquinilo C2-30 sustituido o arilC1-30alquilo sustituido; (3). A2 sea Cys, D-Cys, hCys, D-hCys, Pen o D-Pen; y A9 sea Cys, D-Cys, hCys, D-hCys, Pen o D-Pen; (4). A2 sea Asp o Glu; y A9 sea Dab, Dap, Orn o Lys; y (5). A8 sea Ala o Gly; y A1 no sea NIe; o una sal farmacéuticamente aceptable de dichas sustancias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93472407P | 2007-06-15 | 2007-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066175A1 true AR066175A1 (es) | 2009-08-05 |
Family
ID=40156845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102546A AR066175A1 (es) | 2007-06-15 | 2008-06-13 | Ligandos del receptor de melanocortina de peptidos ciclicos |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100173834A1 (es) |
| EP (1) | EP2167112A4 (es) |
| AR (1) | AR066175A1 (es) |
| TW (1) | TW200848424A (es) |
| WO (1) | WO2008156677A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2555522T3 (es) * | 2007-11-05 | 2016-01-04 | Ipsen Pharma S.A.S. | Uso de melanocortinas para tratar la sensibilidad a la insulina |
| CA2727317C (en) | 2008-06-09 | 2015-02-17 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| NZ596617A (en) | 2009-06-08 | 2014-04-30 | Palatin Technologies Inc | Melanocortin receptor-specific peptides |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| EP2440572B1 (en) | 2009-06-08 | 2017-04-05 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| RU2012108110A (ru) * | 2009-08-05 | 2013-09-10 | Ипсен Фарма С.А.С. | Применение меланокортинов для лечения дислипидемии |
| PL2473518T3 (pl) * | 2009-08-31 | 2017-07-31 | Tensive Controls, Inc. | Stabilizowane ligandy melanokortyny |
| CN102686601A (zh) * | 2009-11-16 | 2012-09-19 | 益普生制药股份有限公司 | 合成Ac-Arg-环(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2的方法 |
| EP2504352B1 (en) | 2009-11-23 | 2018-11-14 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| MX2012005859A (es) | 2009-11-23 | 2012-12-17 | Palatin Technologies Inc | Peptidos lineales especificos del receptor de melanocortina-1. |
| BR112013027222B1 (pt) * | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
| SI3539551T1 (sl) | 2011-12-29 | 2022-02-28 | Rhythm Pharmaceuticals, Inc. | Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih |
| JP6538025B2 (ja) | 2013-03-15 | 2019-07-03 | リズム・ファーマシューティカルズ・インコーポレイテッド | 医薬組成物 |
| RU2020120797A (ru) | 2013-03-15 | 2020-07-02 | Ритм Фармасьютикалз, Инк. | Пептидные композиции |
| AU2019249255A1 (en) * | 2018-04-06 | 2020-11-05 | Alastair GARFIELD | Compositions for treating kidney disease |
| AU2021217939A1 (en) * | 2020-02-03 | 2022-09-15 | Palatin Technologies, Inc. | Reverse amide-linked melanocortin receptor-specific cyclic peptides |
| CN114487398B (zh) * | 2022-01-27 | 2025-07-01 | 西南大学 | 一种抗体复合物、生物传感器及SARS-CoV-2的ECL检测平台和检测方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002238106A1 (en) * | 2001-02-13 | 2002-08-28 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
| US20070105759A1 (en) * | 2003-06-19 | 2007-05-10 | Eli Lilly And Company | Melanocortin receptor 4 (mc4) agonists and their uses |
| EP3925614A3 (en) * | 2005-07-08 | 2022-03-23 | Ipsen Pharma | Melanocortin receptor ligands |
-
2008
- 2008-06-13 TW TW097122036A patent/TW200848424A/zh unknown
- 2008-06-13 US US12/664,695 patent/US20100173834A1/en not_active Abandoned
- 2008-06-13 EP EP08768447A patent/EP2167112A4/en not_active Withdrawn
- 2008-06-13 AR ARP080102546A patent/AR066175A1/es not_active Application Discontinuation
- 2008-06-13 WO PCT/US2008/007411 patent/WO2008156677A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008156677A3 (en) | 2009-04-16 |
| EP2167112A4 (en) | 2012-01-25 |
| US20100173834A1 (en) | 2010-07-08 |
| EP2167112A2 (en) | 2010-03-31 |
| TW200848424A (en) | 2008-12-16 |
| WO2008156677A2 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066175A1 (es) | Ligandos del receptor de melanocortina de peptidos ciclicos | |
| ES2690556T3 (es) | Uso de melanocortinas para tratar la sensibilidad a la insulina | |
| ES2386862T3 (es) | Ligandos de los receptores de la melanocortina | |
| ES2528599T3 (es) | Análogos truncados de un polipéptido insulinotrópico dependiente de glucosa | |
| RU2008104802A (ru) | Лиганды рецепторов меланокортинов | |
| AR061780A1 (es) | Analogos de ghrelina sustituidos en el extremo n- terminal | |
| AR073099A2 (es) | Analogos de ghrelina | |
| RU2003112447A (ru) | Аналоги glp-1 | |
| NZ601175A (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
| ES2259834T3 (es) | Peptidos que contienen lisina para el tratamiento de la enfermedad coronaria. | |
| RU2001118855A (ru) | Аналоги glp-1 | |
| AR043688A1 (es) | Analogos del peptido yy | |
| RU2223970C2 (ru) | Лечение ожирения | |
| CA2625447C (en) | Compositions and methods for stimulating gastrointestinal motility | |
| CN116888146A (zh) | 胰高血糖素样肽-1受体拮抗剂 | |
| CA2769883A1 (en) | Use of melanocortins to treat dyslipidemia | |
| DK168273B1 (da) | Anvendelse af cyclopeptidhjælpestoffer eller fysiologisk acceptable salte deraf som resorptionsfremmende stoffer af peptider og proteiner ved påføring på slimhinder samt farmaceutisk præparat indeholdende disse hjælpestoffer og fremgangsmåde til fremstilling af præparatet | |
| AR076950A2 (es) | Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen | |
| EP3212219A1 (en) | New indication for alpha-msh analogues | |
| HK40067409A (en) | Melanocortin receptor ligands | |
| WO2015063102A1 (en) | Alpha-msh analogues for use in bullous disease | |
| WO2015063099A1 (en) | Alpha-msh analogues for use in the treatment of hailey-hailey disease | |
| HK40019654A (en) | Compositions and methods for stimulating gastrointestinal motility | |
| EP3212220A1 (en) | Inflammatory disease | |
| HK1221147B (en) | Use of melanocortins to treat insulin sensitivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |